Lack Of FDA Trial Authority, DTC Marketing Caused COX-2 Crisis – Topol

Evaluation of naproxen safety should be postponed until final data from NIH's ADAPT trial is released, Cleveland Clinic cardiologist Eric Topol, MD, advocates

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet